Bard expanding presence in vascular graft market via Impra acquisition.
This article was originally published in The Gray Sheet
Executive Summary
BARD TO EXPAND VASCULAR GRAFT PRESENCE VIA IMPRA ACQUISITION by gaining the number two player worldwide in the polytetrafluoroethylene (PTFE) vascular graft market. Bard announced Aug. 5 that it has entered an agreement to acquire Tempe, Arizona-based Impra in a cash transaction "targeted for completion in the third quarter." Terms of the deal were not disclosed.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.